(Q46209126)

English

Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

chelation therapy

0 references

George J Kontoghiorghes

1

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

32

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

608-615

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Light and shadows in the iron chelation treatment of haematological diseases

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Intramuscular desferrioxamine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Essentiality, toxicology and chelation therapy of zinc and copper

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

The effect of synthetic iron chelators on bacterial growth in human serum

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Do we need more iron-chelating drugs?

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

1 reference

https://api.crossref.org/works/10.1080%2F03630260802341703

21 January 2018

Identifiers

10.1080/03630260802341703

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19065341

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46209126&oldid=2099875147"